GlobeNewswire: OSE Immunotherapeutics Contains the last 10 of 175 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:36:14ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853469/0/en/OSE-Immunotherapeutics-Reports-Full-Year-2023-Financial-Results-and-Provides-Business-Strategy-Update.html?f=22&fvtc=4&fvtv=30987OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update2024-03-27T17:00:00Z<![CDATA[Financial highlights]]>https://www.globenewswire.com/news-release/2024/03/27/2853469/0/fr/OSE-Immunotherapeutics-publie-ses-r%C3%A9sultats-financiers-annuels-2023-et-fait-le-point-sur-sa-strat%C3%A9gie-de-d%C3%A9veloppement.html?f=22&fvtc=4&fvtv=30987OSE Immunotherapeutics publie ses résultats financiers annuels 2023 et fait le point sur sa stratégie de développement2024-03-27T17:00:00Z<![CDATA[OSE Immunotherapeutics publie ses résultats financiers annuels 2023 et fait le point sur sa stratégie de développement]]>https://www.globenewswire.com/news-release/2022/07/13/2479228/0/en/OSE-Immunotherapeutics-Appoints-Alexis-Vandier-as-Chief-Executive-Officer.html?f=22&fvtc=4&fvtv=30987OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer2022-07-13T16:00:00Z<![CDATA[NANTES, France, July 13, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately. Alexis Vandier brings an impressive track record of successes in Pharma across a range of international roles and therapeutic areas, including oncology.]]>https://www.globenewswire.com/news-release/2022/06/23/2468313/0/en/OSE-Immunotherapeutics-Reports-on-its-2022-Combined-General-Shareholder-s-Meeting.html?f=22&fvtc=4&fvtv=30987OSE Immunotherapeutics Reports on its 2022 Combined General Shareholder’s Meeting2022-06-23T16:52:41Z<![CDATA[NANTES, France, June 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.]]>https://www.globenewswire.com/news-release/2022/06/16/2463598/0/en/OSE-Immunotherapeutics-Announces-Collaboration-with-Microsoft.html?f=22&fvtc=4&fvtv=30987OSE Immunotherapeutics Announces Collaboration with Microsoft2022-06-16T05:30:00Z<![CDATA[NANTES, France, June 16, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the Company is one of the first biotech startup companies selected by Microsoft France to be a privileged partner of its support program for French Biotech & Deeptech Startups. This program was launched during the 6th edition of “Viva Technology”, the most important Startup and Tech event organized in Europe being held in Paris from June 15-18, 2022.]]>https://www.globenewswire.com/news-release/2022/06/09/2459985/0/en/OSE-Immunotherapeutics-Appoints-its-International-Scientific-Advisory-Board.html?f=22&fvtc=4&fvtv=30987OSE Immunotherapeutics Appoints its International Scientific Advisory Board2022-06-09T16:00:00Z<![CDATA[NANTES, France, June 09, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the appointment of six leading international experts to its newly formed Scientific Advisory Board (SAB) to guide the Company in its next phases of growth and scientific orientations.]]>https://www.globenewswire.com/news-release/2022/06/07/2457276/0/en/Four-Poster-Presentations-at-2022-ASCO-Annual-Meeting.html?f=22&fvtc=4&fvtv=30987Four Poster Presentations at 2022 ASCO Annual Meeting2022-06-07T05:30:00Z<![CDATA[NANTES, France, June 07, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), presented four posters featuring neoepitope specific immunotherapy Tedopi® in various cancer indications at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 4 – 7.]]>https://www.globenewswire.com/news-release/2022/05/23/2448656/0/en/OSE-Immunotherapeutics-Announces-Four-Poster-Presentations-of-Neoepitope-Combination-Tedopi-in-Immuno-Oncology-at-ASCO-2022.html?f=22&fvtc=4&fvtv=30987OSE Immunotherapeutics Announces Four Poster Presentations of Neoepitope Combination Tedopi® in Immuno-Oncology at ASCO 20222022-05-23T16:00:00Z<![CDATA[NANTES, France, May 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four poster presentations* featuring neoepitope combination Tedopi® in various cancer indications at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 4 – 7, 2022 in Chicago.]]>https://www.globenewswire.com/news-release/2022/05/18/2446278/0/en/OSE-Immunotherapeutics-Announces-Dosing-of-the-First-Participant-in-a-Phase-1-Study-of-VEL-101-FR104-a-Novel-Investigational-Drug-for-Kidney-Transplant-Immunosuppression.html?f=22&fvtc=4&fvtv=30987OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression2022-05-18T16:00:00Z<![CDATA[A Phase 1 Study Sponsored and Conducted by Veloxis Pharmaceuticals, Inc., the Company’s Partner in Transplantation]]>https://www.globenewswire.com/news-release/2022/05/11/2441094/0/en/OSE-Immunotherapeutics-To-Present-at-Immuno-Oncology-Summit-Europe-and-at-Tumor-Myeloid-Directed-Therapies-Summit-In-London-and-Boston.html?f=22&fvtc=4&fvtv=30987OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ In London and Boston2022-05-11T16:00:00Z<![CDATA[Presentations to focus on CLEC-1, novel myeloid immune checkpoint target for cancer immunotherapy Presentations to focus on CLEC-1, novel myeloid immune checkpoint target for cancer immunotherapy]]>